2389. Effect of Rezafungin on QT Interval in Healthy Subjects [PDF]
Open Forum Infectious Diseases, 2018 BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation.
Flanagan, Shawn +5 more
openaire +1 more source
Treatment outcomes among patients with a positive Candida culture close to randomization receiving rezafungin or caspofungin in the ReSTORE study [PDF]
BACKGROUND: Rezafungin, a novel, once-weekly echinocandin for the treatment of candidemia and/or invasive candidiasis (IC) was noninferior to caspofungin for day 30 all-cause mortality (ACM) and day 14 global cure in the phase 3 ReSTORE trial ...
et al.,, Kollef, Marin, Soriano, Alex
core +6 more sources
982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [PDF]
Open Forum Infectious Diseases, 2021 Abstract Background Rezafungin (RZF) is a novel echinocandin antifungal being developed for treatment of candidemia and invasive candidiasis, and for prevention of invasive fungal diseases among immunosuppressed patients.
Huguet, Jade +6 more
openaire +1 more source
Journal of Fungi, 2023 The epidemiology of invasive fungal infections (IFIs) is currently changing, driven by aggressive immunosuppressive therapy, leading to an expanded spectrum of patients at risk of IFIs.
Roya Vahedi-Shahandashti +3 more
doaj +1 more source
Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review
Journal of Fungi, 2022 The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel +5 more
doaj +1 more source
New Perspectives on Antimicrobial Agents: Rezafungin. [PDF]
Antimicrob Agents ChemotherABSTRACT Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins.
Forrister NM, McCarty TP, Pappas PG.
europepmc +3 more sources
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data [PDF]
Antimicrobial Agents and Chemotherapy, 2018 ABSTRACT Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. Rezafungin has potent in vitro activity against Candida albicans and Candida glabrata , including ...
Lakota, Elizabeth A. +3 more
openaire +2 more sources
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy [PDF]
Blood Purification, 2018 <b><i>Background/Aims:</i></b> To determine adsorption and transmembrane clearances (CL<sub>TM</sub>) of rezafungin, a novel long-acting echinocandin, in continuous venovenous hemofiltration (CVVH). <b><i>Methods:</i></b> A validated ex vivo bovine blood CVVH model using polysulfone and AN69 ...
Soo Min Jang +2 more
openaire +2 more sources
Guideline adherence and survival of patients with candidaemia in Europe:results from the ECMM Candida III multinational European observational cohort study [PDF]
, 2023 Background: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is ...
core +6 more sources